Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 2
2021 6
2022 7
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
Thornhill JP, Fox J, Martin GE, Hall R, Lwanga J, Lewis H, Brown H, Robinson N, Kuldanek K, Kinloch S, Nwokolo N, Whitlock G, Fidler S, Frater J. Thornhill JP, et al. Among authors: lwanga j. AIDS. 2024 Apr 1;38(5):679-688. doi: 10.1097/QAD.0000000000003825. Epub 2023 Dec 21. AIDS. 2024. PMID: 38133660
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption.
Pace M, Ogbe A, Hurst J, Robinson N, Meyerowitz J, Olejniczak N, Thornhill JP, Jones M, Waters A, Lwanga J, Kuldanek K, Hall R, Zacharopoulou P, Martin GE, Brown H, Nwokolo N, Peppa D, Fox J, Fidler S, Frater J. Pace M, et al. Among authors: lwanga j. Front Immunol. 2022 Aug 30;13:878743. doi: 10.3389/fimmu.2022.878743. eCollection 2022. Front Immunol. 2022. PMID: 36110857 Free PMC article.
GSTM1 Copy Number and Kidney Disease in People With HIV.
Hung RKY, Rosenberg KL, David V, Binns-Roemer E, Booth JW, Hilton R, Fox J, Burns F, Ustianowski A, Cosgrove C, Hamzah L, Burns JE, Clarke A, Chadwick D, Price DA, Kegg S, Campbell L, Bramham K, Sabin CA, Post FA, Winkler CA; GEN-AFRICA Study Group. Hung RKY, et al. Kidney Int Rep. 2022 May 13;7(8):1901-1904. doi: 10.1016/j.ekir.2022.05.003. eCollection 2022 Aug. Kidney Int Rep. 2022. PMID: 35967115 Free PMC article. No abstract available.
Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV.
Hung RKY, Binns-Roemer E, Booth JW, Hilton R, Harber M, Santana-Suarez B, Campbell L, Fox J, Ustianowski A, Cosgrove C, Burns JE, Clarke A, Price DA, Chadwick D, Onyango D, Hamzah L, Bramham K, Sabin CA, Winkler CA, Post FA; GEN-AFRICA Study Group. Hung RKY, et al. Kidney Int Rep. 2022 Jan 25;7(4):786-796. doi: 10.1016/j.ekir.2022.01.1054. eCollection 2022 Apr. Kidney Int Rep. 2022. PMID: 35497797 Free PMC article.
Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV.
Hung RKY, Binns-Roemer E, Booth JW, Hilton R, Fox J, Burns F, Harber M, Ustianowski A, Hamzah L, Burns JE, Clarke A, Price DA, Kegg S, Onyango D, Santana-Suarez B, Campbell L, Bramham K, Sharpe CC, Sabin CA, Winkler CA, Post FA; GEN-AFRICA Study Group. Hung RKY, et al. Kidney Int Rep. 2021 Dec 13;7(3):465-473. doi: 10.1016/j.ekir.2021.12.007. eCollection 2022 Mar. Kidney Int Rep. 2021. PMID: 35257059 Free PMC article.
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Campbell L, Ibrahim F, Barbini B, Samarawickrama A, Orkin C, Fox J, Waters L, Gilleece Y, Tariq S, Post FA; BESTT Trial Team*,†. Campbell L, et al. HIV Med. 2022 Apr;23(4):362-370. doi: 10.1111/hiv.13215. Epub 2021 Dec 5. HIV Med. 2022. PMID: 34866304 Free article. Clinical Trial.
Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study).
Lee MJ, Snell LB, Douthwaite ST, Fidler S, Fitzgerald N, Goodwin L, Hamzah L, Kulasegaram R, Lawrence S, Lwanga J, Marchant R, Orkin C, Palfreeman A, Parthasarathi P, Pareek M, Ring K, Sharaf H, Shekarchi-Khanghahi E, Simons R, Teh JJ, Thornhill J, van Halsema C, Williamson M, Wiselka M, Nori A, Fox J, Smith C. Lee MJ, et al. Among authors: lwanga j. HIV Med. 2022 Feb;23(2):121-133. doi: 10.1111/hiv.13174. Epub 2021 Sep 23. HIV Med. 2022. PMID: 34555242 Free PMC article.
18 results